DB:8AP

Stock Analysis Report

Executive Summary

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of hematologic malignancies, solid tumors, and rare genetic diseases.


Snowflake Analysis

Flawless balance sheet and slightly overvalued.

Share Price & News

How has Agios Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 8AP's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.6%

8AP

-2.3%

DE Biotechs

-0.2%

DE Market


1 Year Return

-2.5%

8AP

8.4%

DE Biotechs

13.7%

DE Market

Return vs Industry: 8AP underperformed the German Biotechs industry which returned 8.4% over the past year.

Return vs Market: 8AP underperformed the German Market which returned 13.7% over the past year.


Shareholder returns

8APIndustryMarket
7 Day7.6%-2.3%-0.2%
30 Day4.5%-3.2%0.3%
90 Day45.0%6.3%3.7%
1 Year-2.5%-2.5%8.6%8.4%17.2%13.7%
3 Year7.6%7.6%44.5%42.9%15.4%5.3%
5 Year-46.8%-46.8%13.0%10.6%21.3%4.7%

Price Volatility Vs. Market

How volatile is Agios Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Agios Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 8AP (€49.27) is trading below our estimate of fair value (€203.59)

Significantly Below Fair Value: 8AP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 8AP is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 8AP is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 8AP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 8AP is overvalued based on its PB Ratio (7.1x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Agios Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

38.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 8AP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 8AP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 8AP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 8AP's revenue (37.4% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: 8AP's revenue (37.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 8AP's Return on Equity is forecast to be low in 3 years time (16.9%).


Next Steps

Past Performance

How has Agios Pharmaceuticals performed over the past 5 years?

-32.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 8AP is currently unprofitable.

Growing Profit Margin: 8AP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 8AP is unprofitable, and losses have increased over the past 5 years at a rate of -32.1% per year.

Accelerating Growth: Unable to compare 8AP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 8AP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 8AP has a negative Return on Equity (-91.79%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Agios Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 8AP's short term assets ($490.1M) exceed its short term liabilities ($92.4M).

Long Term Liabilities: 8AP's short term assets ($490.1M) exceed its long term liabilities ($157.9M).


Debt to Equity History and Analysis

Debt Level: 8AP is debt free.

Reducing Debt: 8AP had no debt 5 years ago.


Balance Sheet

Inventory Level: 8AP has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 8AP's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 8AP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 8AP has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -37.6% each year.


Next Steps

Dividend

What is Agios Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.7%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 8AP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 8AP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 8AP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 8AP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 8AP's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Jackie Fouse (58yo)

1yrs

Tenure

US$537,891

Compensation

Dr. Jacqualyn A. Fouse, also known as Jackie, Ph.D, serves as Director at Incyte Corporation since 2017. Dr. Fouse has served as Executive Chair of Dermavant Sciences, a biopharmaceutical company, since Ju ...


Leadership Team

NamePositionTenureCompensationOwnership
David Schenkein
President & Executive Chairman1yrsUS$8.20m0.65% $22.0m
Jacqualyn Fouse
CEO & Director1yrsUS$537.89k0.061% $2.1m
Andrew Hirsch
CFO & Head of Corporate Development3.4yrsUS$3.14m0.018% $608.1k
Scott Biller
Strategic Advisor0.2yrsUS$3.10m0.13% $4.3m
Christopher Bowden
Chief Medical Officer5.8yrsUS$3.13m0.0024% $81.0k
Lewis Cantley
Co-Founder & Member of Scientific Advisory Board0yrsUS$333.51kno data
Tak Mak
Co-Founder & Member of Scientific Advisory Board0yrsno datano data
Craig Thompson
Co-Founder & Chairman of Scientific Advisory Board0yrsno datano data
Shin-San Su
Co-Founder & Member of Scientific Advisory Board0yrsno datano data
Carman Alenson
Principal Accounting Officer and VP of Accounting3.3yrsno data0.00027% $9.1k

3.3yrs

Average Tenure

63yo

Average Age

Experienced Management: 8AP's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
David Schenkein
President & Executive Chairman1yrsUS$8.20m0.65% $22.0m
Jacqualyn Fouse
CEO & Director1yrsUS$537.89k0.061% $2.1m
Lewis Cantley
Co-Founder & Member of Scientific Advisory Board0yrsUS$333.51kno data
Tak Mak
Co-Founder & Member of Scientific Advisory Board0yrsno datano data
Craig Thompson
Co-Founder & Chairman of Scientific Advisory Board0yrsno datano data
Shin-San Su
Co-Founder & Member of Scientific Advisory Board0yrsno datano data
John Maraganore
Lead Independent Director0yrsUS$581.64k0.048% $1.6m
Kaye Foster-Cheek
Independent Director5.2yrsUS$559.14k0.0053% $177.1k
Paul Clancy
Independent Director6.4yrsUS$554.14k0.0021% $68.9k
Pier Pandolfi
Member of Scientific Advisory Board0yrsno datano data

3.7yrs

Average Tenure

62yo

Average Age

Experienced Board: 8AP's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.5%.


Top Shareholders

Company Information

Agios Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Agios Pharmaceuticals, Inc.
  • Ticker: 8AP
  • Exchange: DB
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$3.626b
  • Listing Market Cap: US$3.360b
  • Shares outstanding: 68.37m
  • Website: https://www.agios.com

Number of Employees


Location

  • Agios Pharmaceuticals, Inc.
  • 88 Sidney Street
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AGIONasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2013
8APDB (Deutsche Boerse AG)YesCommon StockDEEURJul 2013
0HB0LSE (London Stock Exchange)YesCommon StockGBUSDJul 2013
AGIO *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJul 2013

Biography

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML); and treat patients with newly diagnosed AML, as well as is in Phase III clinical trials for treatment of IC eligible frontline AML, IC ineligible frontline AML, and cholangio; Phase I clinical trial for treatment of R/R Myelodysplastic Syndromes; and in preoperative studies for low- grade glioma. It also provides IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation, as well as is in Phase III clinical trial for treatment of IC eligible frontline AML; and Phase I/II clinical trials for the treatment of IC ineligible frontline AML. In addition, it is developing Mitapivat, which is in Phase III clinical trials to treat transfusion independent and dependent pyruvate kinase deficiency; and is in Phase II clinical study for treating thalassemia. Further, the company is developing Vorasidenib that is in Phase III clinical trials for the treatment of low grade glioma; AG-270, which is in Phase I trial to treat methylthioadenosine phosphorylase deleted NSCLC and pancreatic cancer; and AG-636 that is in Phase I stage for lymphoma. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 22:37
End of Day Share Price2020/02/20 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.